Pretty recently, preliminary outcomes from a third demo comparing ibrutinib vs . observation ended up introduced.one zero five Individuals getting ibrutinib experienced an extended occasion-cost-free survival, but no General survival benefit, Even though the success had been continue to immature. Additionally, Though extreme adverse occasions premi